Breaking News

Cryoport Supports Gradalis’ Clinical Trials

To provide cryogenic logistics support for multiple clinical sites throughout the U.S. 

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cryoport, Inc., a cryogenic logistics company for the life sciences, will support Gradalis‘ clinical trials evaluating its investigational Vigil Engineered Autologous Tumor Cell (EATC) immunotherapy technology for use in cancer treatments. Cryoport is currently supporting Gradalis’ Phase II/III trial for high risk stage III/IV ovarian cancer patients, its Phase IIb trial for Ewing’s sarcoma, as well as the pilot combination studies with PD-1/PD-L1 inhibitors, all of which use t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters